目的 研究瑞巴派特联合泮托拉唑治疗幽门螺杆菌(Hp)阴性慢性糜烂性胃炎的临床疗效.方法 选取巴彦淖尔市医院 2020 年 3 月至 2023 年 1 月收治的 85 例Hp阴性慢性糜烂性胃炎患者开展试验.将其按照信封法随机分为试验组 42 例及参考组 43 例.试验组予以瑞巴派特联合泮托拉唑治疗,参考组则予以瑞巴派特联合硫糖铝治疗.比较两组临床疗效,比较治疗前后胃黏膜丙二醛(MDA)及前列腺素E2(PGE2)水平、血清学指标水平、不良反应.结果 试验组治疗总有效率高于参考组(P<0.05).治疗前两组MDA及PGE2水平比较,差异无统计学意义(P>0.05);治疗8周后,试验组MDA水平低于参考组,而PGE2 水平高于参考组,差异有统计学意义(P<0.05).治疗前两组血清血管活性肠肽(VIP)、胃促生长素(Ghrelin)水平比较,差异无统计学意义(P>0.05);治疗8周后,试验组血清VIP水平低于参考组,而Ghrelin水平高于参考组(P<0.05).试验组不良反应总发生率低于参考组(P<0.05).结论 瑞巴派特联合泮托拉唑治疗Hp阴性慢性糜烂性胃炎患者的疗效显著,可改善糜烂组织及血清VIP、Ghrelin水平,降低不良反应风险,值得推广应用.
Objective To study the clinical efficacy of rebamipide combined with pantoprazole in the treatment of Helicobacter pylori(Hp)-negative chronic erosive gastritis.Methods A trial was conducted on 85 patients with Hp-negative chronic erosive gastritis admitted to Bayannur Hospital from March 2020 to January 2023.They were randomly divided into a trial group of 42 cases and a reference group of 43 cases according to the envelope method.The trial group was treated with rebamipide combined with pantoprazole,while the reference group was treated with rebamipide combined with sucralfate.The clinical efficacy,the levels of malondialdehyde(MDA)and prostaglandin E2(PGE2)in the gastric mucosa before and after treatment,the levels of serological indicators before and after treatment,and adverse reactions of the two groups were compared.Results The total effective rate of the trial group was higher than that of the reference group(97.62%vs.83.72%)(P<0.05).There was no statistically significant difference in MDA and PGE2 levels between the two groups before treatment(P>0.05).After 8 weeks of treatment,the MDA level in the trial group was lower than that in the reference group,while the PGE2 level was higher than that in the reference group,with statistically significant differences(P<0.05).There were no statistically significant differences in the levels of serum vasoactive intestinal peptide(VIP)and ghrelin between the two groups before treatment(P>0.05).After 8 weeks of treatment,the serum VIP level in the trial group was lower than that in the reference group,while the ghrelin level was higher than that in the reference group(P<0.05).The total incidence of adverse reactions in the trial group was lower than that in the reference group(4.76%vs.18.60%)(P<0.05).Conclusion The combination of rebamipide and pantoprazole has a significant efficacy on patients with Hp-negative chronic erosive gastritis,which can improve the levels of VIP and ghrelin in erosive tissues and serum,reduce the risk of adverse reactions,and is worthy of promotion and application.